Safety and Efficacy Evaluation of IM19 CAR-T Cells

  • STATUS
    Not Recruiting
  • participants needed
    60
  • sponsor
    Beijing Immunochina Medical Science & Technology Co., Ltd.
Updated on 22 January 2021
fludarabine
cyclophosphamide
chronic lymphocytic leukemia
rituximab
monoclonal antibodies
combination chemotherapy
monoclonal antibody therapy

Summary

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-all.

Description

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-ALL patients and determine the MTD,LTD and the best dosage.

Details
Condition leukemia
Treatment IM19 CAR-T
Clinical Study IdentifierNCT03142646
SponsorBeijing Immunochina Medical Science & Technology Co., Ltd.
Last Modified on22 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note